PTCT Stock Analysis: PTC Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.264m USD | 12M Return: 30.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 107M
Qual. Beats: 0
Rev. Trend: 43.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PTC Therapeutics, Inc. is a U.S.-based biopharmaceutical company headquartered in Warren, New Jersey, that discovers, develops, and commercializes treatments for rare disorders globally. Its marketed portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (marketed as Kebilidi in the U.S.) for AADC deficiency, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy.
The companys development pipeline targets additional rare conditions, including Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease, and vatiquinone for Friedreichs ataxia, supported by platforms in splicing, inflammation, and ferroptosis. As a rare disease specialist, PTC relies on third-party distributors for product delivery and maintains strategic collaborations and licensing agreements with major partners such as Roche, Novartis, the SMA Foundation, and Akcea Therapeutics.
- DMD franchise Translarna and Emflaza sales face regulatory headwinds
- Evrysdi SMA royalties from Roche expand as prescriptions grow
- PTC518 Huntingtons program milestone payments from Novartis advance
| Net Income: -38.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -25.07 > 1.0 |
| NWC/Revenue: 183.0% < 20% (prev 93.21%; Δ 89.82% < -1%) |
| CFO/TA -0.01 > 3% & CFO -30.5m > Net Income -38.4m |
| Net Debt (1.68b) to EBITDA (155.1m): 10.81 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.0m) vs 12m ago 17.75% < -2% |
| Gross Margin: 92.89% > 18% (prev 97.09%; Δ -4.20% > 0.5%) |
| Asset Turnover: 34.28% > 50% (prev 67.00%; Δ -32.72% > 0%) |
| Interest Coverage Ratio: 0.76 > 6 (EBIT TTM 116.3m / Interest Expense TTM 152.2m) |
| A: 0.57 (Total Current Assets 2.62b - Total Current Liabilities 771.1m) / Total Assets 3.25b |
| B: -0.89 (Retained Earnings -2.88b / Total Assets 3.25b) |
| C: 0.04 (EBIT TTM 116.3m / Avg Total Assets 2.94b) |
| D: -0.05 (Book Value of Equity -165.4m / Total Liabilities 3.42b) |
| Altman-Z'' = 1.05 = BB |
| DSRI: 2.13 (Receivables 239.0m/196.1m, Revenue 1.01b/1.76b) |
| GMI: 1.05 (GM 97.09% / 92.89%) |
| AQI: 1.66 (AQ_t 0.16 / AQ_t-1 0.09) |
| SGI: 0.57 (Revenue 1.01b / 1.76b) |
| TATA: -0.00 (NI -38.4m - CFO -30.5m) / TA 3.25b) |
| Beneish M = -1.97 (Cap -4..+1) = B |
As of August 02, 2026, the stock is trading at USD 68.01 with a total of 4,327,693 shares traded. Over the past week, the price has changed by -11.47%, over one month by -16.62%, over three months by +4.53% and over the past year by +30.51%.
Current recommended Stop Loss: 60.80 (which is 10.6% or 2.3 ATR below the current price).
PTC Therapeutics has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PTCT.
- StrongBuy: 5
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 96.1 | 41.3% |
P/E Forward = 38.9105
P/S = 7.5738
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 1.01b USD
EBIT TTM = 116.3m USD
EBITDA TTM = 155.1m USD
Long Term Debt = 2.03b USD (from longTermDebt, last fiscal year)
Short Term Debt = 73.4m USD (from shortTermDebt, last quarter)
Debt = 2.21b USD (corrected: LT Debt 2.03b + ST Debt 73.4m) + Leases 108.2m
Net Debt = 1.68b USD (calculated: Debt 2.21b - CCE 531.1m)
Enterprise Value = 7.94b USD (6.26b + Debt 2.21b - CCE 531.1m)
Interest Coverage Ratio = 0.76 (Ebit TTM 116.3m / Interest Expense TTM 152.2m)
EV/FCF = 138.2x (Enterprise Value 7.94b / FCF TTM 57.4m)
FCF Yield = 0.72% (FCF TTM 57.4m / Enterprise Value 7.94b)
FCF Margin = 5.69% (FCF TTM 57.4m / Revenue TTM 1.01b)
Net Margin = -3.80% (Net Income TTM -38.4m / Revenue TTM 1.01b)
Gross Margin = 92.89% ((Revenue TTM 1.01b - Cost of Revenue TTM 71.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 85.47%)
Tobins Q-Ratio = 2.44 (Enterprise Value 7.94b / Total Assets 3.25b)
Interest Expense / Debt = 6.90% (Interest Expense 152.2m / Debt 2.21b)
Taxrate = 2.01% (14.0m / 696.6m)
NOPAT = 113.9m (EBIT 116.3m * (1 - 2.01%))
Current Ratio = 3.29 (Total Current Assets 2.62b / Total Current Liabilities 796.6m)
Debt / Equity = -13.35 (negative equity) (Debt 2.21b / totalStockholderEquity, last quarter -165.4m)
Debt / EBITDA = 10.81 (Net Debt 1.68b / EBITDA 155.1m)
Debt / FCF = 29.17 (Net Debt 1.68b / FCF TTM 57.4m)
Total Stockholder Equity = -176.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.30% (Net Income -38.4m / Total Assets 3.25b)
RoE = 21.72% (negative equity) (Net Income TTM -38.4m / Total Stockholder Equity -176.7m)
RoCE = 6.29% (EBIT 116.3m / Capital Employed (Equity -176.7m + L.T.Debt 2.03b))
RoIC = 4.55% (NOPAT 113.9m / Invested Capital 2.50b)
WACC = 7.55% (E(6.26b)/V(8.47b) * Re(7.83%) + D(2.21b)/V(8.47b) * Rd(6.90%) * (1-Tc(0.02)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.44 | Cagr: 8.56%
[DCF] Terminal Value 73.10% ; FCFF base≈317.3m ; Y1≈278.2m ; Y5≈224.8m
[DCF] Fair Price = 23.30 (EV 3.61b - Net Debt 1.68b = Equity 1.93b / Shares 82.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.28 | # QB: 0
Revenue Correlation: 43.94 | Revenue CAGR: 18.31% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.48 | Chg30d=+1.42% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=1.32 | Chg30d=+0.51% | Revisions=+25% | GrowthEPS=-82.7% | GrowthRev=-31.7%
EPS next Year (2027-12-31): EPS=2.74 | Chg30d=-1.56% | Revisions=+25% | GrowthEPS=+107.6% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +40% (up=2, down=0)